Skip to main content

Promising Cancer Break Through Might Stop Cancer In Its Tracks




It's a promising cancer break through that might be able to stop cancer in its tracks and it was discovered by Michigan State University researchers.
It has to do with visceral fat.
We have two layers of fat. The outer layer or subcutaneous fat which is the easiest to lose and doesn't pose as much of a health risk.
The second layer is visceral fat. That’s the fat that’s tucked deep inside, next to the organs. This fat has been shown to play a very dangerous role in affecting hormones and their function. Those hormones are what trigger the grow of cancers like breast, lung and colon because those cancers are strongly influenced by our hormones.
The MSU study is now zoning in on this. Researchers are testing a promising drug called I-BET-762 that is showing signs of delaying the development of existing breast and lung cancer cells by targeting a how a cancerous gene in the visceral fat works.
The drug does not allow the gene to express itself, therefore significantly reducing the number of cancer cells produced.
In human tests, the drug prevented more than 50-percent of the cells from becoming cancerous.
A significant breakthrough in cancer research especially since almost half a million of all new cancers are linked to obesity and this visceral fat.







Comments

Post a Comment

Popular posts from this blog

Get the Facts About Genetic Colon Cancer

Get the Facts: http://genefacts.org Lynch syndrome is a cancer predisposition syndrome caused by inherited mutations in genes responsible for correcting DNA replication errors. Individuals with Lynch syndrome have a greatly increased risk for colorectal, endometrial, and stomach cancers, and a moderately increased risk for other cancers. Key Points 1-3% of colon cancers attributable to Lynch syndrome Dominant inheritance with reduced penetrance (not all patients with mutations will manifest disease) Diagnosis based on clinical and family history, tumor pathology and/or genetic testing Screening and prophylactic surgeries effective in reducing some, but not all cancer risks Mutations in any of several genes can cause the syndrome
Post a Comment
Read more

Cancer Survivors

Just read a story about one woman's cancer experience. I bet everyone has a story about what goes through your mind when you are told you have cancer. Her thought were about her stunned family members, one crying and the other in shock. I bet there are quite a few stories that could be qualitatively studied. Those experiences could help nurses better help patients during this time.
1 comment
Read more

My Publication, "Hereditary non-polyposis colon cancer: change the name to protect the innocent." Cited in World Journal of Gastroenterology

Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration t... Hsi-Hsien Hsu, Wei-Wen Kuo, Da-Tong Ju... World journal of gastroenterology : WJG 11/2014 20(44):16665-73. World Journal of Gastroenterology : WJG 11/2014; 20(44):16665-73. DOI: 10.3748/wjg.v20.i44.16665 Source: PubMed ABSTRACT To investigate the effects of 17β-estradiol via estrogen receptors (ER) or direct administration of ER agonists on human colorectal cancer. LoVo cells were established from the Bioresource Collection and Research Center and cultured in phenol red-free DMEM (Sigma, United States). To investigate the effects of E2 and/or ER selective agonists on cellular proliferation, LoVo colorectal cells were treated with E2 or ER-selective agonists for 24 h and 48 h and subjected to the MTT (Sigma) assay to find the concentration. And investigate the effects of E2 and/or ER selective agonists on cell used western immunoblotting to find out the diver...
Post a Comment
Read more